Date: 2013-04-22
Type of information: R&D agreement
Compound: therapeutic antibodies
Company: Kymab (UK) Novo Nordisk (Denmark)
Therapeutic area: undisclosed
Type agreement: R&D
licensing
Action mechanism:
Disease: undisclosed
Details: Kymab, a monoclonal antibody biopharmaceutical company, has announced an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive licence to Kymab\'s proprietary Kymouse™ human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases.
The licence provides Novo Nordisk with access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, which can generate highly selective, potent, human antibody drug candidates. The Kymouse HL strain produces antibodies with human heavy and lambda light chains whereas Kymouse HK generates antibodies with human heavy and kappa light chains. By using these strains in combination, a diverse pool of human antibodies can be created with both classes of light chains fully represented.
Financial terms: The financial terms of the agreement were not disclosed, but include platform licence fees, development milestone payments for drug candidates and royalties on sales of antibodies discovered using the Kymouse strains.
Latest news:
